Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada

We identified an influenza B isolate harboring a Gly407Ser neuraminidase substitution in an immunocompromised patient in Canada before antiviral therapy. This mutation mediated reduced susceptibility to oseltamivir, zanamivir, and peramivir, most likely by preventing interaction with the catalytic A...

Descripción completa

Detalles Bibliográficos
Autores principales: Abed, Yacine, Fage, Clément, Lagüe, Patrick, Carbonneau, Julie, Papenburg, Jesse, Vinh, Donald C., Boivin, Guy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2019
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433030/
https://www.ncbi.nlm.nih.gov/pubmed/30882323
http://dx.doi.org/10.3201/eid2504.181554
_version_ 1783406239177244672
author Abed, Yacine
Fage, Clément
Lagüe, Patrick
Carbonneau, Julie
Papenburg, Jesse
Vinh, Donald C.
Boivin, Guy
author_facet Abed, Yacine
Fage, Clément
Lagüe, Patrick
Carbonneau, Julie
Papenburg, Jesse
Vinh, Donald C.
Boivin, Guy
author_sort Abed, Yacine
collection PubMed
description We identified an influenza B isolate harboring a Gly407Ser neuraminidase substitution in an immunocompromised patient in Canada before antiviral therapy. This mutation mediated reduced susceptibility to oseltamivir, zanamivir, and peramivir, most likely by preventing interaction with the catalytic Arg374 residue. The potential emergence of such variants emphasizes the need for new antivirals.
format Online
Article
Text
id pubmed-6433030
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-64330302019-04-03 Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada Abed, Yacine Fage, Clément Lagüe, Patrick Carbonneau, Julie Papenburg, Jesse Vinh, Donald C. Boivin, Guy Emerg Infect Dis Research Letter We identified an influenza B isolate harboring a Gly407Ser neuraminidase substitution in an immunocompromised patient in Canada before antiviral therapy. This mutation mediated reduced susceptibility to oseltamivir, zanamivir, and peramivir, most likely by preventing interaction with the catalytic Arg374 residue. The potential emergence of such variants emphasizes the need for new antivirals. Centers for Disease Control and Prevention 2019-04 /pmc/articles/PMC6433030/ /pubmed/30882323 http://dx.doi.org/10.3201/eid2504.181554 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research Letter
Abed, Yacine
Fage, Clément
Lagüe, Patrick
Carbonneau, Julie
Papenburg, Jesse
Vinh, Donald C.
Boivin, Guy
Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada
title Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada
title_full Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada
title_fullStr Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada
title_full_unstemmed Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada
title_short Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada
title_sort reduced susceptibility to neuraminidase inhibitors in influenza b isolate, canada
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433030/
https://www.ncbi.nlm.nih.gov/pubmed/30882323
http://dx.doi.org/10.3201/eid2504.181554
work_keys_str_mv AT abedyacine reducedsusceptibilitytoneuraminidaseinhibitorsininfluenzabisolatecanada
AT fageclement reducedsusceptibilitytoneuraminidaseinhibitorsininfluenzabisolatecanada
AT laguepatrick reducedsusceptibilitytoneuraminidaseinhibitorsininfluenzabisolatecanada
AT carbonneaujulie reducedsusceptibilitytoneuraminidaseinhibitorsininfluenzabisolatecanada
AT papenburgjesse reducedsusceptibilitytoneuraminidaseinhibitorsininfluenzabisolatecanada
AT vinhdonaldc reducedsusceptibilitytoneuraminidaseinhibitorsininfluenzabisolatecanada
AT boivinguy reducedsusceptibilitytoneuraminidaseinhibitorsininfluenzabisolatecanada

Ejemplares similares